Posted on Authorea 8 Jun 2020 | The copyright holder is the author/funder. All rights reserved. No reuse without permission. | https://doi.org/10.22541/au.159164636.66131121 | This a preprint and has not been peer reviewed. Data may be preliminary. nie etsgi sal sdi cenn n igoi.UfruaeyPAi o acrseicand specific not is PSA Unfortunately diagnosis. and screening in used usually is cancer. testisng antigen and procalcitonin between Known: higher relationship What’s significantly the was and define levels CRP to PCT Serum needed Serum are respectively. 2. studies groups group in in years 0.04 Conclusion: 69.41 and and 4.07 group 66.85 PCa. in was with 0.01 patients patients and in the the 3.33 of was to age levels according mean PCT groups The Statistical two 2. MedCalc into group divided cancer. were analyses. prostate patients statistical Results: group2; for The and used procalci- hyperplasia was study. 17.6 prostate the the version benign measure in Software to group1; included were aimed reports, years we pathology 4 study last this the In PCa. with patients diagnosis. in Methods: PCa levels for (CRP) protein C-reactive used and most tonin(PCT) the is antigen Cancer Prostate in Aim: levels Procalcitonin cancer. and prostate in protein associated levels is of C-reactive procalcitonin procalcitonin precursor not the of a investigated is level is e elevated PSA study The Procalcitonin Unfortunately this cells. New: In neuroendocrine diagnosis. What’s sepsis. some and management. the and and cancer screening cancer C-cells bacteremia define common thyroid in prostate with by to most for used produced second needed needed usually is the are which are is Conclusion: is studies testisng was new cancer PCa. Further antigen levels and with Prostate specific PCT patients specific Known: cancer. and Prostate in cancer What’s higher CRP prostate significantly men. Serum with cancer. was elderly respectively. levels associated prostate among groups PCT patients and was in Serum 31 procalcitonin levels years and 2. between 69.41 procalcitonin group1 group relationship and elevated in in 66.85 0.04 patients that was and 118 pathology found patients 4.07 were the We group the There to in used of according patients. was 0.01 age groups 149 and 17.6 mean two version includes 3.33 The into prostate Software study divided Statistical transurethral 2. current were MedCalc group The and patients in cancer. biopsy Results: The prostate prostate study. analyses. group2; (CRP) transrectal the and statistical protein most underwent in hyperplasia for C-reactive the prostate included who and is were benign patients procalcitonin(PCT) antigen years group1; the The specific 4 reports, measure Prostate last Methods: to world. the aimed the in PCa. we in surgery study men with among this patients cancer In in common diagnosis. levels most PCa the for of one biomarker is used (PCa) cancer Prostate Aim: Abstract 2020 8, June 2 1 Ilktac Abdullah cancer? prostate in biomarker results new Preliminary a be procalcitonin Can ea pca Hospital Special FakultesiReyap Tip Universitesi Vakif Bezmialem rsaecne Pa soeo h otcmo acraogmni h ol.Pott specific Prostate world. the in men among cancer common most the of one is (PCa) cancer Prostate h urn td nlds19ptet.Teewr 1 ainsi ru1ad3 ainsin patients 31 and group1 in patients 118 were There patients. 149 includes study current The h ainswoudrettasetlpott ipyadtasrtrlpott ugr in surgery prostate transurethral and biopsy prostate transrectal underwent who patients The efudta lvtdpoactnnlvl a soitdwt rsaecne.Further cancer. prostate with associated was levels procalcitonin elevated that found We 1 rsaecne stescn otcmo acraogedrymn rsaespecific Prostate men. elderly among cancer common most second the is cancer Prostate ea Kalkan Senad , 1 n eaatn¸Calı¸skan Selahattin and , 1 2 Posted on Authorea 8 Jun 2020 | The copyright holder is the author/funder. All rights reserved. No reuse without permission. | https://doi.org/10.22541/au.159164636.66131121 | This a preprint and has not been peer reviewed. Data may be preliminary. h igoi a aeb rsaebos n9 ainsadpott ugr n5 ains(Table-2). patients 57 detected was in 7 and surgery 6 prostate GS 2; and group ng/ml patients In 0.04 (p<0.05). 92 groups and in in mg/L method 4.07 biopsy diagnosis for 1, prostate difference group significant by was in made There PCT). ng/ml for was 0.01 p<0.05 diagnosis and and in mg/L The CRP higher 3.3 for significantly was was (p=0.08 levels 66.85 level 2 PCT was PSA group and patients The in CRP characteristics. the Serum patients’ of 2. the age shows group mean 1 Table The (p=0.10). 2. Software respectively Group Statistical in MedCalc were of patients ( version levels 2017). and demo PSA www.medcalc.org; cell different http:// the Results: Belgium; in blood using Ostend, levels white performed bvba, PCT Software were were and and (MedCalc curves PSA,CRP analyses neutrophil version17.6 characteristic(ROC) The total Statistical age, operating utility receiver mean ng/ml). the diagnostic test. The as >10 for the U significance. expressed assess median statistical Mann-Whitney were to with sedimentation with analyzed Data considered and compared as PCT values. were 0.05 CRP, percentage p< others PSA, for the variable free used and distribution was PSA, test normal test The t squared 2. independent test. chi group Kolmogorov-Smirnov with in the compared was with PCa was analyzed and proliferation(n:4) was acinar 1 normality small Group Distribution atypical in and study. divided was (n:3) the were neoplasia hyperplasia from patients intraepithelial prostate excluded prostatic the were grade benign examination; PCT high with prostate CRP, pathological of PSA, patients and the results free cores The The After PSA, ten The radiotherapy, excluded. groups. procedures. least position. two of were at the lithotomy into history position ng/ml) with before anestesia decubitus patients measured (>100 general lateral were The or PSA with levels spinal of anesthesia under study. made level local the was under high surgery in made and was included prostatitis biopsy were The chronic 2019 malignancy, June therapy, and dutasteride 2016 In patients January the levels. compared between PCT and patients with cancer association prostate Methods: reaction an in inflammatory levels have PCT systemic and the cell CRP In C-cells malignancy. renal measure without throid (2). to and calcitonin by aimed thyroid of we produced study, as precursor this is such a is malignancies (PCT) it cell some Procalcitonin and squamous and cells oral . neuroendocrine malignancies; urogenital some CRP some In cancer, and , in of hepatocellular endometrial diseases. prognosis , levels cancers, cancer, autoimmun poor High lung and breast cell to small (6). infarction linked and liver trauma, non-small been esophagealcarcinoma, the infection, have carcinoma, levels microbial in CRP with produced elevated associated is addition, usually proteinwhich are acute-phase fold) an (1000 is (2,4,5). PCa (CRP) urinary (prostatehealthindex, of protein and biomarkers diagnosis C-reactive new hyperplasia for testing and investigated serum prostate velocity) were additional PSA benign and PSA, procalcitonin) limited prostatitis, free/total and is density, fourkallikrein as testing PSA PSA ( such of PSA specific; diseases use from organ are the derivated is diagnosed benign sensitivity, testing it be adequate marker, in PSA its specific may seen and cancer (1,4).Despite patients not retention (DRE) are The is examination PSA levels Unfortunatelly PCa(2). rectal elevated of (4). (3).Digital so PCa screening disease of testing and diagnosis metastatic (PSA) early diagnosis antigen for to the important specific indolent for prostate clinically Serum test from used (1). as commonly population most general the the in is malignancy common most fifth study Introduction: this In sepsis. cancer. and Words: prostate bacteremia Key in with levels associated procalcitonin is the procalcitonin investigated of e level Elevated cells. neuroendocrine New: management. cancer What’s prostate for needed are biomarkers new hr ee19ptet nti td.O hs ains 1 ainswr nGop n 31 and Group1 in were patients 118 patients; these Of study. this in patients 149 were There h ainswoudrettasetlpott ipyadtasrtrlpott surgery prostate transurethral and biopsy prostate transrectal underwent who patients The rsaecne,poactnn -ecieprotein C-reactive procalcitonin, cancer, prostate rsaecne(C)i n ftems omncne mn ae ntewrdadthe and world the in males among cancer common most the of one is cancer(PCa) Prostate rclioi sapeusro actnnwihi rdcdb hodCclsadsome and C-cells throid by produced is which calcitonin of precursor a is Procalcitonin 2 + .9ad69.41 and 8.19 ± + tnaddvainfor deviation standard .0yasi groups in years 6.20 < 0and 10 Posted on Authorea 8 Jun 2020 | The copyright holder is the author/funder. All rights reserved. No reuse without permission. | https://doi.org/10.22541/au.159164636.66131121 | This a preprint and has not been peer reviewed. Data may be preliminary. rsaetm nlwrs rsaecne ainswoaeeiil o ciesrelac:Hwsf si to it is safe How surveillance: active for 2019;79(13):1523-1529. eligible Prostate. are pathology? who bioptic patients on cancer depend prostate low-risk new in A prostatectomy cancer: prostate in levels 3) procalcitonin down- Serum its A. 85(2):46-50. and Otunctemur 1975-1983. Journal.2018; level I, 51(11): Urologia O,Alkan arginine biomarker?. 2019; Can plasma Nephrol. HA, of Atalay Urol importance L, Int 2)Canat The cancer. O. prostate Kaymaz diagnosing K, in N,Murat metabolites Baydilli stream H, Basar I, 1)Selvi REFERENCES future. the in our cancer Acknowledgements support prostate studies diagnose further to If biomarker cancer. new prostate Funding: a with patients be in can one higher of PCT were from stage serum levels .The patients findings PCT levels of serum the number that measuring small found first homogenous. of We a after not efficacy again was includes diagnostic checked PCT. PCa study not high and with were This a PSA patients PCT) study. found between the (CRP, current We difference parameters the (2). significant the ng/ml in and no PCT center 2-20 and limitations that of ng/ml some level >10 found ara Turkey level PSA There from PSA a a a authors be with may with PCa The value patients of (15). PCT in diagnose carcinoma that PCT to cell reported nun- used authors clearr and be the calcitonin localized carcinoma addition, can of the medullary In and prediction of inflammation (16,17). PCT that investigated for precursor showed between were biomarker studies a relationship cancer The and lung is (14,15). tumorgenesis cell sepsis which for small and and kDa PCT role bacteremia of for important 13 level marker an the of a plays increases as weight cytokines investigated and a been circulating has infections; with it fungal and protein bacterial amino-acid During (14). patients CRP 116 hormone with and a correlated risk (12). and is PCa metastasis PCa Procalcitonin between without in and association factor than cancer prognostic no metastasis a prostate found bone was cancer, authors had CRP bladder the who that carcinoma, contrary demonstrated cell the authors pro- renal The On promotion, levels(13). as cancers. C-reactive initiation, such (12). tract cancer cancers transformation urinary with in urological neoplastic upper the role and associated hyperplasia predict important is to can an increases cells CRP protein has atherosclerotic IL-6 endocrine inflammation of in of stimulates inflammation;activation Systemic Synthesis rarely metastasis the CRP. gression, and In (11). of T-cells. liver level body and in serum macrophages the the from produced in secretion mainly (IL-6) alveolarmacrophages ng/ml is 6 4.01-10 and interleukin which level neurons protein PSA kidney, acutphase in lesions, an diagnosis is PCa protein for C-reactive efficacy found velocity, PCa(4).We diagnostic and from significant density diseases has prostate PSA benign test, (5). ratio To differentiate was score PSA respectively(10). to kallikrein rate used ng/ml free/total four detection was 20.01-50 that than marker index, value cancer and PCA3 health predictive the ratio, 10.01-20 positive Prostate PSA study, higher 4-10, (1). cancer free/total have previous investigated which of for markers our been level between and PSA have In is PSA molecules PSA of new rate ng/ml. with biopsies; detection value 4-10 patients unnecessary cancer in of the threshold the reduce value 54.2% biopsy, no cancer PSA and age, for not the is 34.5 a recommended but is is there 22.3, with is PSA unknown testing and ng/ml patients But is PSA 4 in diseases (9). over Serum PCa 20-25% PCa prostate PSA (8). especially of general benign etiology diseases In cause in prostatic the diagnosis(1). main for increases on biomarker (7).The marker, focused used worldwide are specific and in factors accepted environmental cancer widely patients. and most lung 2 diet and after factors, in7,4 deaths 10 genetic cancer and 8,9 of as cause reported was score Gleason Discussion: respectively. patients 7 and 11 in ee ,re ,OlkYKlcsa ,SniO za .Teptooia prdn fe radical after upgrading pathological The F. Ozcan O, Sanli I, Y,Kilicaslan Ozluk S, S,Erdem Verep None C stems omnmlgac nmnodrta 0yasadtescn otcommon most second the and years 60 than older men in malignancy common most the is PCa None : 3 Posted on Authorea 8 Jun 2020 | The copyright holder is the author/funder. All rights reserved. No reuse without permission. | https://doi.org/10.22541/au.159164636.66131121 | This a preprint and has not been peer reviewed. Data may be preliminary. otdfile Hosted procalcitonin-be-a-new-biomarker-in-prostate-cancer-preliminary-results 1.docx IP, tablo Kema JW, Groot de with file M¨uller-Brand 31-40. J, patients Hosted M, in 116: survival 2010; lin progression-free roid Kr¨anz Cancer. - and cancer. F, - course thyroid clinical Iten thy medullary predict T, with levels Radimerski Procalcitonin patients M¨uller TP, B. C, among Links Meier carcinoma 1477-1481. MA, thyroid 51: Walter 2013; lary 17) Med. - Lab medul Chem detecting Clin in nodules. procalcitonin C- and sensitive 2015;83(4):225- calcitonin high carcinoma. serum cell preoperative renal 16) cell increased clear of of Evaluation stage and S. 2016 grade Baltacı on Microbiol. 230. levels E, New procalcitonin Suer and review. MI, protein literature reactive Gokce Care a N, Supportive Hamidi oncology: for 15) Network clinical Italian in M2; procalcitonin Danova of A1, Antonuzzo Use Jul;39(3):174-180. G3, (NICSO). Comolli Oncology M2, in Torchio markers A1, used commonly Sbrana other 14) and protein C-reactive Hammar Cancer of L, Cancer.2011:15;129(6):1485-92. levels Holmberg J IntJ with M, associated Lambe inflammation. Pac not A, of Hayday is meta-analysis.Asian E, cancer Binda prostate and H, of Garmo Risk review G, N. significance Walldius Prognostic I, systematic ZQ. Jungner Ye M, a ZQ, Hemelrijck 13)Van Chen H, Xu cancers: C- YQ, urological O. Zhang W, 2014;15(8):3369-75. Strobel in Li Prev. J, T, protein Zeng Endocr G, Hackert Yu C-reactive W, F, of Xiao neoplasms. K, Bergmann Tang neuroendocrine J1, M, Dai pancreatic Schenk 12) in Y, properties Li malignant M, 2019:8;1007-1019. promotes Herbst Connect. (CRP) K, Felix protein Y, reactive Yang S, 11)Schimmack 2018;14:1256-9. [?]100 of ResTher 2016 level Subcli- Can antigen Urol. of J prostate-specific Population.Curr with Biomarkers ng/ml. men General Turkish and among the cancer Levels ¸Calı¸skan prostate from 10) PSA of Men Prevelance between S. Healthy Association Middle-Aged R. in Oct;9(3):148-152. Borgquist Inflammation B, Systemic cancer Rezanezhad prostate nical 2018;71(2):242-247. between S, Urol. levels J Elzanaty acid European uric 9) Cent serum group. of control Comparison Y¨uce A a SN, after Ayyıldız and failure A, patients biochemical Cirakoglu and E, pathology, Benli adverse 8) 2011;27:307-13. prostate, percentage MedSci the of among J side can- correlation dominant Kaohsiung The AO. prostate the prostatectomy. Akdemir from radical BK, localized cores Aktas CV, biopsy clinically C-reactive Oztekin positive C, serum with of Ozden O, preoperative patients Ugurlu Do A, in Memis AJ. 7) stage Schrader pathological F, prostate- Jentzmik definitive ;47(5):765-70. total K, 2015 the of cer? Steinestel predict levels J, levels Steinestel intermediate protein TJ, and Schnoeller ng/ml) ([?]4 6) 2017;13:279-83. concentration ResTher the low Can for J in ratio (4.01–10.0ng/ml). cancer antigen specificantigen of prostate-specific prostate diagnosis antigen/total the of prostate-specific in diagnosis free important be of pH efficacy urine 5)CaliskanS.Diagnostic Can 31:391560319865724. perspective: Jul different 2019 A Yah¸si cancer?Urologia. S. OG, prostate Doluoglu C, Ceylan 4) ivnlaL ebr A meil ,Vlbe-g ,Tibl ,CraiL oprsno serum of Comparison L. Ceriani P, Trimboli S, ga - Valabre M, Imperiali FA, Verburg L, Giovanella vial at available https://authorea.com/users/330882/articles/457690-can- 4 Posted on Authorea 8 Jun 2020 | The copyright holder is the author/funder. All rights reserved. No reuse without permission. | https://doi.org/10.22541/au.159164636.66131121 | This a preprint and has not been peer reviewed. Data may be preliminary. procalcitonin-be-a-new-biomarker-in-prostate-cancer-preliminary-results table-2.docx vial at available https://authorea.com/users/330882/articles/457690-can- 5